Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Semaglutide

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

The approval accelerates a shift toward oral GLP-1 treatments that promise wider, steadier access.

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

New Study Finds Nearly Fivefold Higher Reported ‘Eye Stroke’ Risk With Wegovy vs Ozempic

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects